EFFECT OF CYCLOSPORIN A ON TCR ONTOGENY AND AUTOIMMUNE DISEASE
环孢菌素 A 对 TCR 个体发育和自身免疫性疾病的影响
基本信息
- 批准号:3791878
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:T cell receptor T lymphocyte autoantibody autoimmune disorder biological signal transduction bone marrow transplantation cell growth regulation cell migration cell sorting chickens cyclosporines disease /disorder model embryo /fetus cell /tissue gene expression genetic strain immune tolerance /unresponsiveness immunocytochemistry immunoregulation immunosuppression laboratory mouse monoclonal antibody passive immunization pathologic process phenotype radiation dosage receptor expression thymectomy thymus
项目摘要
Recent observations indicate that cyclosporin A (CsA) blocks TCR initiated
signal transduction and thus leads to abnormal TCR repertoire selection.
CsA treatment can lead to overt autoimmune disease in two different
experimental models. In both these models, the development of disease
requires both the presence of autoreactive cells derived from the CsA
treated thymus and an immunoregulatory abnormality in peripheral T cells.
Preliminary data suggest that CsA inhibits thymic selection of the TCR2
(alphabeta TCR) repertoire, but not thymic maturation of the TCR1
(gammadelta TCR) sublineage. The broad, long-term objectives of these
studies are to determine the physiologic function of these different T cell
sublineages and to elucidate the nature of the peripheral immunoregulatory
activity involved in tolerance. The specific aims are to test three
hypotheses.
The first hypothesis is that CsA inhibits both positive and negative
selection of the TCR2 repertoire in the thymus, but does not affect thymic
TCR1 cell maturation. This hypothesis will be tested by determining the
effect of CsA on thymic ontogeny utilizing a panel of mAb which recognize
different TCRs and associated molecules. These studies will involve
analysis of both murine and chicken T cell development. The focus will be
on the selection of cells expressing particular Vbeta genes in the mouse
and the maturation of the TCR3 subset, a novel alphabeta-like TCR, in the
chicken.
The second hypothesis is that the TCR1 repertoire is selected in peripheral
tissue. This hypothesis will be tested by examination of the development
and tissue homing pattern of TCR1 cells expressing particular Vgamma and
Vdelta genes. Two experimental approaches will be used: 1) determining if
CsA treatment results in inhibition of specific tissue homing patterns
characteristic of TCR1 cells which utilize certain Vgamma genes. 2)
intrathymic injection of FITC to identify recent thymic emigrants in
peripheral tissues and the determining the pattern of Vgamma usage in these
cells.
The third hypothesis is that in models of CsA induced autoimmune disease,
TCR2 cells mediate autoreactivity, while TCR1 cells regulate disease
activity. Two different experimental models will studied: 1) neonatal CsA
plus thymectomy and 2) lethally irradiated adults rescued with syngeneic BM
transplant plus Ca treatment. These models will be established and the
frequency and histologic localization of the different T cells sublineages
will be characterized by immunohistochemical staining and FACS analysis.
In both these models, the presence of "normal" T cells blocks the ability
of autoreactive T cells induce actual tissue lesions. The phenotype of
both the autoreactive effector cells and the "normal" regulatory cells will
be determined using magnetic activated cell sorting and an adoptive
transfer protocol.
最近的观察表明,环孢菌素 A (CsA) 可以阻断 TCR 启动
信号转导,从而导致 TCR 库选择异常。
CsA 治疗可导致两种不同的明显自身免疫性疾病
实验模型。 在这两种模型中,疾病的发展
需要来自 CsA 的自身反应细胞的存在
治疗的胸腺和外周 T 细胞的免疫调节异常。
初步数据表明 CsA 抑制 TCR2 的胸腺选择
(alphabeta TCR) 全部功能,但不是 TCR1 的胸腺成熟
(gammadelta TCR)亚系。 这些目标的广泛、长期目标
研究的目的是确定这些不同 T 细胞的生理功能
亚谱系并阐明外周免疫调节的本质
涉及耐受性的活动。 具体目标是测试三个
假设。
第一个假设是 CsA 同时抑制正向和负向
胸腺中TCR2库的选择,但不影响胸腺
TCR1 细胞成熟。 该假设将通过确定
利用一组识别 CsA 的 mAb 对胸腺个体发育的影响
不同的 TCR 和相关分子。 这些研究将涉及
小鼠和鸡 T 细胞发育分析。 重点将是
小鼠中表达特定 Vbeta 基因的细胞的选择
以及 TCR3 子集(一种新型的类似 Alphabeta 的 TCR)的成熟
鸡。
第二个假设是 TCR1 库是在外设中选择的
组织。 这个假设将通过检查发展来检验
以及表达特定 Vgamma 和 TCR1 细胞的组织归巢模式
Vdelta基因。 将使用两种实验方法:1)确定是否
CsA 治疗可抑制特定组织归巢模式
利用某些 Vgamma 基因的 TCR1 细胞的特征。 2)
胸腺内注射 FITC 来识别最近的胸腺迁移
外周组织和确定 Vgamma 在这些组织中的使用模式
细胞。
第三个假设是,在 CsA 诱导的自身免疫性疾病模型中,
TCR2 细胞介导自身反应,而 TCR1 细胞则调节疾病
活动。 将研究两种不同的实验模型:1) 新生儿 CsA
加上胸腺切除术和 2) 用同基因 BM 拯救受致命辐射的成年人
移植加钙治疗。 这些模型将被建立并
不同 T 细胞亚系的频率和组织学定位
将通过免疫组织化学染色和 FACS 分析来表征。
在这两种模型中,“正常”T 细胞的存在阻碍了这种能力
自身反应性 T 细胞会诱发实际的组织损伤。 表型为
自身反应性效应细胞和“正常”调节细胞都会
可以使用磁激活细胞分选和过继来确定
传输协议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
R PAT BUCY其他文献
R PAT BUCY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('R PAT BUCY', 18)}}的其他基金
EFFECT OF CYCLOSPORIN A ON TCR ONTOGENY AND AUTOIMMUNE DISEASE
环孢菌素 A 对 TCR 个体发育和自身免疫性疾病的影响
- 批准号:
3747677 - 财政年份:
- 资助金额:
-- - 项目类别:
EFFECT OF CYCLOSPORIN A ON TCR ONTOGENY AND AUTOIMMUNE DISEASE
环孢菌素 A 对 TCR 个体发育和自身免疫性疾病的影响
- 批准号:
3769886 - 财政年份:
- 资助金额:
-- - 项目类别:
EFFECT OF CYCLOSPORIN A ON TCR ONTOGENY AND AUTOIMMUNE DISEASE
环孢菌素 A 对 TCR 个体发育和自身免疫性疾病的影响
- 批准号:
3804220 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual